ArticleMikrochimica acta2026
Hydrogel based substrate controllable release for lateral flow assay with automatic signal amplification.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The limited sensitivity of conventional lateral flow assay (LFA) restricts its application in detecting trace targets. Although nanozyme-based LFAs could enhance detection performance significantly, they typically introduce additional steps, including the mixing and addition of the substrate for incubation, complicating the assay procedure. To circumvents this, we developed a hydrogel-integrated LFA platform (HG-LFA) by incorporating a sodium alginate (NaAlg) hydrogel network on a glass fiber membrane for encapsulating the chromogenic substrate 3,3'-diaminobenzidine (DAB). This three-dimensional network enables controllable release of DAB, automatically enhancing signal amplification with low background interference. Using SARS-CoV-2 E nucleic acid as a model target, the assay achieved a LOD of 0.146 nM, representing a 25-fold improvement over conventional Au@PtNPs-based LFA without signal amplification. After DAB catalysis, the signal enhancement of the HG-LFA that automatically releases the chromogenic substrate was comparable to that achieved by manual addition. In addition, the HG-LFA platform demonstrated high accuracy and stability in the detection of the target compound in biological matrix, offering a facile strategy well-suited for point-of-care testing (POCT) with high performance.
Indexed as
Identifiers
41483023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.